Extended Data Fig. 8: HSF1 drives MHC-I expression and tumor immunity.
From: LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
a, B16-OVA cells were treated with IFNγ in the presence or absence of KRIBB11 for 48 hours. Cell surface expression of OVA-H2-Kb was determined by FACS. mean ± SD, n = 4 biological independent samples, P value by 2-sided t-test. b, B16-OVA cells were pretreated with IFNγ in the presence or absence of KRIBB11 for 48 hours, then cultured with OT-1 T cells. Cell death was determined by 7-AAD staining in the CD45- tumor cells. mean ± SD, n = 3 biological independent samples, P value by 2-sided t-test. c, MHC-I (H2-Dd) surface staining of CT26 shFluc or shHsf1 cells treated with IFNγ for 48 hours. mean ± SD, n = 3 biological independent samples, P value by 2-sided t-test. d, YUMM1.7 shFluc or shHsf1 cells were treated with IFNγ in the presence or absence of KRIBB11 for 48 hours. Surface expression of MHC-I (H2-Db) was determined by FACS. mean ± SD, n = 3 biological independent samples, P value by 2-sided t-test. e, Dot plots of CD3+, Ki67+, IFNγ+, and TNFα+ T cells in YUMM1.7 shFluc or shHsf1 tumors. f, Tumor growth curve of CT26 shFluc or shHsf1 tumors in BALB/c mice. mean ± SD, n = 6 animals, P value by 2-sided t-test for end point tumor volume. g, Percentages of CD3+, IFNγ+, TNFα+, and Ki67+ T cells in CT26 shFluc or shHsf1 tumors. mean ± SD, n = 5 biological independent samples, P value by 2-sided t-test. h, Dot plots of CD3+, Ki67+, IFNγ+, and TNFα+ T cells in CT26 shFluc or shHsf1 tumors. Source data are provided.
